Lipocalin-2 (LCN2) has been implicated in a variety of processes including cell differentiation, tumorigenesis and apoptosis. Polymorphisms in the expression of LCN2 are associated with many cancers such as breast, colorectal, pancreatic, ovarian, gastric, thyroid, ovarian, bladder and kidney cancers.
